Compound Evidence File
#EC-2026-0907
T4 (Levothyroxine)
Filed under Oral Tablets. The bureau holds 133 laboratory returns for this compound from 49 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
49 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 6 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 4 | 10.0 | 9.9 | 10.0 | 26 Dec 2025 | 16 Jun 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 4 | 10.0 | 10.0 | 10.0 | 21 Nov 2025 | 4 Jun 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 4 | 10.0 | 10.0 | 10.0 | 20 Mar 2026 | 18 Jun 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 4 | 10.0 | 9.9 | 10.0 | 6 Feb 2026 | 2 Jun 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 3 | 10.0 | 9.9 | 10.0 | 4 Feb 2026 | 25 Jun 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 3 | 10.0 | 10.0 | 10.0 | 15 Mar 2026 | 4 Jul 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 3 | 10.0 | 10.0 | 10.0 | 5 Jan 2026 | 10 Apr 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 3 | 10.0 | 10.0 | 10.0 | 13 Feb 2026 | 13 Mar 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 3 | 10.0 | 9.9 | 10.0 | 4 Feb 2026 | 18 Apr 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 3 | 10.0 | 10.0 | 10.0 | 25 Jan 2026 | 1 Jul 2026 |
| SinoPepCASE #VI-2026-0387 | A | 2 | 10.0 | 10.0 | 10.0 | 9 Jun 2026 | 24 Jun 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 2 | 10.0 | 10.0 | 10.0 | 7 Jun 2026 | 20 Aug 2026 |
| Bulk Peptide WholesaleCASE #VI-2026-0319 | X | 1 | 10.0 | 10.0 | 10.0 | 3 Jun 2025 | 3 Jun 2025 |
| Peptide TechnologiesCASE #VI-2026-0694 | X | 1 | 10.0 | 10.0 | 10.0 | 28 Mar 2025 | 28 Mar 2025 |
| HomopeptideCASE #VI-2026-0760 | A | 4 | 9.9 | 9.9 | 10.0 | 24 May 2026 | 24 May 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 4 | 9.9 | 9.9 | 10.0 | 15 Dec 2025 | 14 Aug 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 4 | 9.9 | 9.9 | 10.0 | 11 Dec 2025 | 18 Aug 2026 |
| AsymchemCASE #VI-2026-0091 | A | 4 | 9.9 | 9.9 | 10.0 | 22 Apr 2026 | 10 Jul 2026 |
| BachemCASE #VI-2026-0314 | A | 3 | 9.9 | 9.9 | 10.0 | 18 Nov 2025 | 12 Jul 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 3 | 9.9 | 9.9 | 10.0 | 28 Jan 2026 | 24 May 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 3 | 9.9 | 9.9 | 9.9 | 5 May 2026 | 25 Jun 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 3 | 9.9 | 9.9 | 10.0 | 22 Apr 2026 | 18 Aug 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 2 | 9.9 | 9.9 | 9.9 | 9 Mar 2026 | 11 May 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 2 | 9.9 | 9.9 | 9.9 | 13 May 2026 | 24 Jun 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 3 | 9.3 | 8.6 | 10.0 | 21 May 2026 | 21 May 2026 |
| Hunan Ruiwang Technology CenterCASE #VI-2026-0027 | X | 1 | 9.1 | 9.1 | 9.1 | 6 May 2025 | 6 May 2025 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 7 | 8.8 | 7.3 | 9.6 | 24 May 2026 | 24 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 6 | 8.6 | 7.0 | 9.5 | 24 May 2026 | 24 May 2026 |
| Shanghai Leader Peptide BiotechnologyCASE #VI-2026-0558 | X | 1 | 8.6 | 8.6 | 8.6 | 6 May 2025 | 6 May 2025 |
| ZZQ PeptidesCASE #VI-2026-0550 | X | 1 | 8.6 | 8.6 | 8.6 | 16 Mar 2025 | 16 Mar 2025 |
| Top PeptideCASE #VI-2026-0721 | X | 1 | 8.6 | 8.6 | 8.6 | 25 Apr 2025 | 25 Apr 2025 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 4 | 8.2 | 7.3 | 9.5 | 24 May 2026 | 24 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 3 | 7.9 | 7.5 | 8.3 | 25 May 2026 | 25 May 2026 |
| Pure Tested PeptidesCASE #VI-2026-0225 | X | 1 | 7.8 | 7.8 | 7.8 | 2 Apr 2025 | 2 Apr 2025 |
| Welon Peptide SolutionsCASE #VI-2026-0478 | X | 1 | 7.6 | 7.6 | 7.6 | 16 Mar 2025 | 16 Mar 2025 |
| SRY LabsCASE #VI-2026-0657 | X | 10 | 7.5 | 5.6 | 10.0 | 3 Jun 2025 | 17 May 2026 |
| Huaian Hanyou PeptideCASE #VI-2026-0297 | X | 1 | 7.5 | 7.5 | 7.5 | 24 Apr 2025 | 24 Apr 2025 |
| Haikou Mingheng TechnologyCASE #VI-2026-0250 | X | 1 | 7.1 | 7.1 | 7.1 | 14 Jan 2025 | 14 Jan 2025 |
| Mix PeptidesCASE #VI-2026-0699 | X | 2 | 6.6 | 5.0 | 8.2 | 16 Mar 2025 | 20 May 2026 |
| Kerisite Shenzhen InternationalCASE #VI-2026-0315 | X | 1 | 6.4 | 6.4 | 6.4 | 7 May 2025 | 7 May 2025 |
| YimeiCASE #VI-2026-0081 | X | 3 | 5.9 | 4.9 | 6.5 | 3 Jul 2025 | 24 May 2026 |
| Accelerate LabsCASE #VI-2026-0686 | X | 2 | 5.4 | 5.2 | 5.6 | 13 Feb 2025 | 19 Jan 2026 |
| Oasis PeptidesCASE #VI-2026-0404 | X | 1 | 5.4 | 5.4 | 5.4 | 25 Apr 2025 | 25 Apr 2025 |
| Hangzhou Youngpeptide Biotechnology HYBCASE #VI-2026-0347 | X | 1 | 5.4 | 5.4 | 5.4 | 2 Apr 2025 | 2 Apr 2025 |
| Amplified AminoCASE #VI-2026-0748 | X | 1 | 5.0 | 5.0 | 5.0 | 8 Jul 2025 | 8 Jul 2025 |
| Chimera PeptidesCASE #VI-2026-0260 | X | 1 | 4.0 | 4.0 | 4.0 | 24 Apr 2025 | 24 Apr 2025 |
| Coastal PeptidesCASE #VI-2026-0958 | X | 1 | 3.7 | 3.7 | 3.7 | 25 Apr 2025 | 25 Apr 2025 |
| Amino AmigosCASE #VI-2026-0061 | X | 1 | 3.3 | 3.3 | 3.3 | 28 Mar 2025 | 28 Mar 2025 |
Open any subject to view the batch-level evidence for T4 (Levothyroxine) alone.